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Background: Arsenic trioxide is effective in treating promyelocytic leukemia, and laboratory studies demonstrate
that arsenic trioxide causes apoptosis of human breast cancer cells. Region II in northern Chile experienced very
high concentrations of inorganic arsenic in drinking water, especially in the main city Antofagasta from 1958
until an arsenic removal plant was installed in 1970.
Methods:We investigated breast cancermortality from1950 to 2010 amongwomen in Region II compared to Re-
gion V, which had low arsenic water concentrations.We conducted studies on human breast cancer cell lines and
compared arsenic exposure in Antofagasta with concentrations inducing apoptosis in laboratory studies.
Findings: Before 1958, breast cancer mortality rates were similar, but in 1958–1970 the rates in Region II were
half those in Region V (rate ratio RR= 0.51, 95% CI 0.40–0.66; p b 0.0001). Women under the age of 60 experi-
enced a 70% reduction in breast cancer mortality during 1965–1970 (RR = 0.30, 0.17–0.54; p b 0.0001). Breast
cancer cell culture studies showed apoptosis at arsenic concentrations close to those estimated to have occurred
in people in Region II.
Interpretation:We found biologically plausible major reductions in breast cancer mortality during high exposure
to inorganic arsenic in drinkingwaterwhich could not be attributed to bias or confounding.We recommend clin-
ical trial assessment of inorganic arsenic in the treatment of advanced breast cancer.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Arsenic has been used therapeutically for more than 2400 years for
many different conditions (Antman, 2001). Following initial studies in
China in the early 1980s (Zhou, 2012; Wang and Chen, 2008), arsenic
trioxide—along with retinoic acid—has become the treatment of choice
for relapsed promyelocytic leukemia, usually resulting in complete re-
mission of this highly fatal rare disease (Soignet et al., 1998; Gallagher,
1998). Apoptosis occurs in human promyelocytic leukemia cells ex-
posed to arsenic trioxide in laboratory studies (Iriyama et al., 2013).
The idea that human breast cancer might also be treatable with arsenic
arose fromﬁndings of apoptosis in human breast cancer cells exposed to
arsenic trioxide (Xia et al., 2012; Wang et al., 2011; Du et al., 2012; Li
et al., 2004; Chow et al., 2004). Several mechanisms have beenool of Public Health, University
keley, CA 94720-7360, United
. This is an open access article underproposed. For example, arsenic has been shown to cause induction of
functional re-expression of the estrogen receptor in estrogen negative
breast cancer cells, which could make them less aggressive (Du et al.,
2012). Breast cancer remains a major cause of death in the United
States and other countries. Mortality has reduced in the last few de-
cades, but less so for estrogen-negative cancers (Jatoi et al., 2007).
Chile is divided into regions, and Region II in northern Chile is ex-
tremely dry (the driest inhabited location on earth), with no private
wells or alternative water sources, so the entire population uses munic-
ipal water. Before 1958, the water of the major city of Antofagasta
contained about 90 μg/L arsenic. In 1958, a new system was installed
which involved piping water from distant river sources; between 1958
and 1970, arsenic water concentrations averaged 870 μg/L (Marshall
et al., 2007). In 1970, an arsenic removal plant was installed and arsenic
levels dropped sharply to about 110 μg/L. Arsenic removal has improved
and the city water now contains less than 10 μg/L, which is the World
Health Organization recommendation for maximum arsenic concentra-
tions in drinkingwater (World Health Organization, 2011). Other smallerthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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during overlapping periods, although not as high as in Antofagasta
(Smith et al., 1998).
We have previously demonstrated markedly increased mortality in
Region II of Chile from cancers of the lung, bladder, and kidney, starting
about ten years after high exposure commenced, with increased risks
continuing decades after exposure reduction (Marshall et al., 2007;
Smith et al., 1998; Steinmaus et al., 2013; Yuan et al., 2010). These ﬁnd-
ings are consistent with other studies, and arsenic in drinking water is
now an established cause of lung and bladder cancers (International
Agency for Research on Cancer, 2004). However, in assessing all causes
of death from 1950 to 2010, wewere surprised to see that breast cancer
mortality was actually reduced during the high exposure period. This
paper reports these ﬁndings in light of the potential therapeutic role
of inorganic arsenic.
2. Methods
Computerized mortality data were available for all of Chile after
1970, but not before. We therefore designed a mortality study com-
paring death rates in Region II with Region V from 1950 to 2010,
since it would have been prohibitively expensive to code death cer-
tiﬁcates before 1970 for the whole country. For the years 1950–
1970, we digitally photographed all death certiﬁcates (218,000) for
Region II and Region V; they were then coded by trained nosologists
according to the International Classiﬁcation of Diseases, Ninth
Revision (ICD-9). Death certiﬁcate data from both regions were
intermingled after computer entry, and nosologists were kept blind
as to the region from which death certiﬁcates came. After 1970,
coded computerized mortality data were obtained from the Instituto
Nacional de Estadística de Chile.
2.1. Arsenic Exposure Data
Weobtainedwater arsenic concentrations for Region II of Chile (Smith
et al., 1998; Ferreccio et al., 2000), and concentrations for the city of Anto-
fagasta are plotted in Fig. 1. The nearby town of Mejillones shared the
same water source, so that about 50% of the population of Region II
would have experienced these very high exposures. We also obtained
arsenic water concentrations for other cities and towns in Region II,
most of which also had increased arsenic concentrations in their water.
For example, the second largest city of Calama with a population of
100,283 had arsenic water concentrations above 200 μg/L until 1978,
when arsenic removal commenced in that city (Smith et al., 1998).0
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Fig. 1. Age-adjusted breast cancer rate ratios and 95% conﬁdence intervals, comparing Region II
the midpoint of the 5-year period, starting with the estimate for 1950–1954, which is plotted
Antofagasta.2.2. Comparison Population
We selected Region V of Chile as a comparison population because it
was considerably larger than Region II, giving good statistical power,
and had never experienced signiﬁcant population exposure to arsenic
in drinkingwater. For example, themajor city of this region (Valparaíso,
with a population of about 300,000 in 1970) has arsenic water concen-
trations close to 1 μg/L (Yuan et al., 2010). A survey of Valparaíso urine
arsenic concentrations had an average of 15 μg/L in 1984 (Venturino,
1991), a level typically found in low exposure populations. To check
that Region V was an appropriate comparison population with regard
to other characteristics, we compared census information for the years
1952, 1960 and 1970.
2.3. Statistical Analysis
To investigate the temporal relation of breast cancer and ovarian
cancer mortality to changes in the water concentration of arsenic, we
categorized calendar years into four time periods on the basis of expo-
sure in Region II: 1950–1957 (low exposure), 1958–1970 (high expo-
sure), 1971–2000 (low-moderate exposure), and 2001–2010 (low
exposure). We estimated breast cancer (ICD-9 code 174) and ovarian
cancer (ICD-9 code 183) mortality rate ratios (RRs) using Poisson
regression analysis comparing Region II with Region V, with adjustment
for age in 10-year strata from 30 to 80 years of age (SAS version 9.3, SAS
Institute, Inc., Cary, NC).
2.4. Breast Cancer Cell Line Studies and Arsenic Concentrations
Weconducted studies to investigate the toxic effects of arsenic triox-
ide on human cancer cells in vitro, using the breast cancer cell lines
MCF7, MDA-MB-468, BT474, and SKBR3, and the noncancerous breast
cell line MCF10A. Following 72 h of treatment with As2O3 at varying
concentrations between 0.1 and 40 μM, breast cancer cell viability was
measured. Breast cancer cells were also treated with 0.5, or 4.5 μM
As2O3 for 72 h, and assessed by immunoblot analysis. Methodological
details are given in Supplementary Materials p 1.
3. Results
Table 1 presents the census demographic data available for 1952,
1960, and 1970. There were higher percentages of men, consistent
with extensive mining activities in Region II. Other factors, including
the percentage of births to mothers under the age of 20, were similar0
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with Region V, 1950–2010. Each point represents an estimate for 5 years and is plotted at
at the year 1952. Gray histograms show arsenic concentration in the drinking water in
Table 1
Demographic comparisons of Region II with Region V using available census data for 1952, 1960, and 1970.
Region II Region V
1952 1960 1970 1952 1960 1970
Total population 184,824 215,219 251,906 498,254 617,510 738,336
Urban 89.3% 94.8% * 85.3% 88.8% *
Female 46.6% 48.7% 49.7% 52.0% 52.3% 52.5%
Literate 86.0% 92.8% * 85.5% 91.9% *
Economically active 54.6% 49.3% 42.8% 51.8% 46.3% 41.9%
Birth rate per 1000 35.0 32.4 24.2 28.2 31.1 22.6
Births to mothers under 20 12.1% 13.2% * 11.0% 10.6% *
Births to mothers over 40 3.4% 3.2% * 4.4% 3.9% *
*Data not in census.
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gion II with Region V or all of Chile (Smith et al., 2012) are summarized
in SupplementaryMaterials p 2. Nomajor differences have been appar-
ent in any factors that might have ameaningful impact on breast cancer
mortality.
Table 2 presents breast cancermortality RRs separated into themain
exposure periods (Supplementary Materials p 3 gives more detailed
age-group data). Before 1958, breast cancer mortality was about the
same in Regions II and V (mortality rate ratio RR = 1.07, 95% CI 0.78–
1.47). Breast cancer mortality reduced in Region II in the period 1958–
70 relative to RegionV (RR= 0.51, CI 0.40–0.66; p b 0.0001). The differ-
ence was most pronounced among women under the age 60 who had
70% lower mortality in Region II than in Region V in the second part of
the high exposure period, 1965–70 (RR = 0.30, CI 0.17–0.54;
p b 0.0001). Thereafter, mortality from breast cancer remained a little
lower in Region II than Region V, but the differences became much
smaller, and by the years 2001–2010, the all-ages combined RR was
0.87, CI 0.77–0.99.
Fig. 1 plots the age-adjusted breast cancer mortality RRs comparing
Region II with Region V. The arsenic removal plant in Antofagasta com-
menced operations in 1970 and mortality from breast cancer in Region
II started to increase again soon after. In SupplementaryMaterials p 4–5,
we present mortality year by year before, during and after the high
exposure period. The Region V breast cancer mortality rates increased
gradually over the years, similar to increases reported inmany countries
(Hermon and Beral, 1996). Although the numbers in any one year are
relatively small, the data suggest that breast cancer mortality in Region
II started to reducewhen the high exposures commenced in 1958. After
the arsenic removal plant was installed, mortality rates in Region II
gradually increased again until they became close to those in Region
V. Since the period of very high exposure in Antofagasta, there haveTable 2
Breast and ovarian cancers and all other cause deaths andmortality rate ratios (RRs) comparing
in drinking water.
Age group 1950–57 low exposure in Region II 1958–70 high exposure in Region II
Region RR 95% CI Region RR 95% CI
II V II V
Breast cancer
30+ total 47 201 1.07 (0.78–1.47) 64 598 0.51 (0.40–0.6
30–59 26 109 1.01 (0.66–1.55) 30 318 0.42 (0.29–0.6
60+ 21 92 1.16 (0.72–1.86) 34 280 0.64 (0.45–0.9
Ovarian cancer
30+ total 12 32 1.68 (0.87–3.27) 18 137 0.62 (0.38–1.0
30–59 8 22 1.54 (0.69–3.47) 10 80 0.55 (0.29–1.0
60+ 4 10 2.03 (0.63–6.47) 8 57 0.74 (0.35–1.5
All other causes
30+ total 3066 14,995 0.98 (0.94–1.02) 5932 30,732 0.97 (0.94–0.9
30–59 1277 5358 1.00 (0.94–1.06) 1993 9218 0.94 (0.90–0.9
60+ 1789 9637 0.96 (0.91–1.01) 3939 21,514 0.98 (0.95–1.0
a Excluding 1976 since no data were obtained for that year due to political unrest.been ﬂuctuations in breast cancer mortality in Region II, with continua-
tion of exposure in many locations. For example, the small town of Chiu
Chiu had high concentrations of arsenic in thewater (750 μg/L) until the
installation of an arsenic removal system in 2001 (Smith et al., 2000;
Mac-Lean et al., 2003).
We also examined ovarian cancer mortality; in the high exposure
period, the RR reduced to 0.62 (95% CI 0.38–1.02; 2-tailed p = 0.06).
Sincewith ovarian cancerwe had a clear a priori hypothesis thatmortal-
ity might be reduced based on our breast cancer ﬁndings, we also calcu-
lated a 1-tailed test of signiﬁcance (p = 0.03). As with breast cancer
mortality, the mortality RR was even lower among women aged 30–
59 (RR = 0.55, 95% CI 0.29–1.06; 1-tailed p = 0.04). However, the
differences between Region II and Region V ovarian cancer mortality
were mainly due to a marked increase in Region V (from 3.05 to 6.18
per 100,000), whereas the reduction in Region II rates was relatively
small (from 4.82 to 3.52 per 100,000, Supplementary Materials p 6).
Reasons for the marked increase in Region V are not known, but data
back to 1960 from Greece, Italy and Spain also show similar marked
increases in ovarian cancer mortality (Bray et al., 2005).
3.1. Treatment of Breast Cancer in Chile
We investigated breast cancer treatment in Chile in the 1950s and
1960s. Research on new breast cancer treatmentmethodswas conduct-
ed in University Medical Schools in the capital of Santiago (Lucchini
et al., 1962), and not in Region II. Discussions with clinicians in Antofa-
gasta gave no evidence of any special treatment for breast cancer which
differed from that in the rest of Chile or Region V. The standard treat-
ment prior to 1970 was radical mastectomy, sometimes followed by
radiotherapy. There was no hint of any treatment changes in Region II
of Chile in 1958–1970 which could explain our ﬁndings.Region II in four arsenic exposure periodswith Region Vwhichwas not exposed to arsenic
1971–2000 low-moderate exposure in
Region IIa
2001–2010 low exposure in Region II
Region RR 95% CI Region RR 95% CI
II V II V
6) 443 2756 0.76 (0.68–0.83) 280 1437 0.87 (0.77–0.99)
1) 215 1197 0.72 (0.62–0.83) 138 516 0.95 (0.79–1.15)
2) 228 1559 0.79 (0.69–0.91) 142 921 0.81 (0.68–0.97)
2) 148 593 1.18 (0.99–1.42) 82 399 0.91 (0.72–1.16)
6) 64 243 1.07 (0.81–1.41) 36 144 0.90 (0.62–1.29)
5) 84 350 1.28 (1.01–1.63) 46 255 0.92 (0.68–1.27)
9) 20,249 96,927 1.09 (1.08–1.11) 9968 45,185 1.15 (1.12–1.17)
9) 4643 16,726 1.11 (1.07–1.15) 1864 5354 1.23 (1.17–1.30)
1) 15,606 80,201 1.09 (1.07–1.11) 8104 39,831 1.13 (1.11–1.16)
Fig. 2.Analysis of the effects of As2O3 on breast cancer cell lines. MCF10A,MCF7, MDA-468, BT474, and SKBR3 cells were treatedwith physiologically relevant concentrations of As2O3 and
evaluated at 72 h for cell viability (A), and apoptosis by immunoblotting (B) or Annexin-V staining (C). Panel A: cell viability was assessed by Alamar Blue assay. Results are expressed as
the percent of live cells relative to untreated controls. The data represent mean values of three experiments. Panel B: PARP cleavage was detected by immunoblotting and was used as an
indication for apoptosis. Actin level wasmeasured as a loading control. Panel C: apoptotic cells were quantiﬁed using aMuse™ Annexin V & Dead Cell Assay Kit. Results are expressed as a
percentage of total cells.
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Fig. 2 (Panel A) presents our ﬁndings for human breast cancer cell
lines grown up to 72 h in varying concentrations of As2O3 and assessed
by Alamar Blue assay (Supplementary Materials p 1). These cell lines
are representative of the major molecular subtypes of breast cancer, in-
cluding HER2/Neu-positive (SKBR3 and BT474), ER-positive (MCF7),
and triple negative/basal-like (MDA-MB-468). Results for the non-
tumorigenic immortalized breast epithelial cell line MCF10A are also
shown in Fig. 2. In contrast to the breast cancer cells, MCF10A cells
demonstrated no reduction in cell viability from As2O3 treatments at
or below 2.5 μM, although viability signiﬁcantly declined at higher
concentrations. BT474, SKBR3, and MCF7 cells demonstrated similar
responses to escalating concentrations of As2O3, with cell viability im-
paired at the lowest effective doses of 1.25, 2.5, and 2.5 μM, respectively.
MDA468 cell viability was signiﬁcantly impaired at As2O3 concentra-
tions as low as 0.3 μM. In all cell lines tested, treatment with As2O3 at
concentrations greater than 5 μMproduced signiﬁcant cytotoxic effects.
To investigate themechanismbywhich arsenic induces cell cytotox-
icity, cell lines were grown for 72 h in As2O3 (0, 0.5 or 4.5 μM) and apo-
ptosis was examined by immunoblot analysis of PARP cleavage (Fig. 2).
In all cell lines tested, treatment with 4.5 μMAs2O3 induced cleavage of
endogenous 116 kDa PARP into 85 kDa fragments, indicating the occur-
rence of apoptotic cell death. Treatment with 0.5 μM As2O3 induced
apoptosis in MCF7, MDA-MB-468, and BT474 cells, but not in SKBR3
or MCF10A cells. Arsenic-induced cell death was also assessed using a
Muse™ Annexin V & Dead Cell Assay (Fig. 2, Panel B). Consistent with
the immunoblot analysis, Annexin-V staining showed that 72 h of treat-
ment with 4.5 μM As2O3 produced signiﬁcant apoptosis in all cell lines
tested (Panel C).
The ﬁndings fromhuman cancer breast cell lineswould indicate that
a concentration of 1–2 μM arsenic trioxide is having apoptotic effects
with just a few days of exposure. This concentration is close to the
human exposure to inorganic arsenic we estimated to have occurred
in Antofagasta during the high exposure period (Supplementary Mate-
rials p 7).4. Discussion
We have previously reported markedly increased mortality in Re-
gion II of Chile from now well established arsenic-related cancers
(Marshall et al., 2007; Smith et al., 1998; Steinmaus et al., 2013; Yuan
et al., 2010; Ferreccio et al., 2000, 2013). Carcinogenic effects follow
arsenic exposure with long latency intervals, usually starting more
than ten years after exposure commences, and in the case of lung and
bladder cancer, going on even 40 years after exposure reduction
(Steinmaus et al., 2013). The reduction in breast cancer mortality in
Region II of Chile started quickly after exposure commenced (Supple-
mentary Materials p 4–5), and the trend reversed soon after exposures
were reduced in Antofagasta in 1970. The city of Calama, and a number
of smaller towns and villages, continued to have high arsenic exposure
after 1970, in some cases even up to the year 2000. We believe these
exposures may account for the continuing low breast cancer mortality,
but we have no satisfactory explanation for the RR reaching about 1 in
1978 and then going down again (Fig. 1). The error bars raise the possi-
bility that there was some random ﬂuctuation in numbers.
The decrease in breast cancer mortality in Region II during the
highest exposure period cannot be attributed to chance, with tests of
signiﬁcance yielding p-values less than 0.001. In fact, using the Proc
Genmod procedure in SAS for Poisson regression analysis, the test of
statistical signiﬁcance for reduced breast cancer mortality in Region II
in the period 1958–1970 yielded a p-value of less than 1 in a million.
We therefore focus on whether or not the ﬁndings could be attributed
to confounding or information bias, and assess biological plausibility.
4.1. Confounding
It is inconceivable that ﬁndings we present concerning breast cancer
could be due to confounding. There are several reasons for this: 1) Risk
factors, such as genetics, ethnic composition, age atmenarche, and envi-
ronmental factors such as those related to diet, obesity, smoking and al-
cohol consumption, could not have changed rapidly enough in the total
population of Region II to account for reduced breast cancer mortality
62 A.H. Smith et al. / EBioMedicine 1 (2014) 58–63compared to Region V starting in 1958, and then reversed themselves
rapidly to account for increased mortality starting in 1971; 2) Changes
in socioeconomic status and lifestyle are most unlikely to occur in a
manner reducing only breast and ovarian cancer mortality, and not
mortality from other causes. In contrast to the breast cancer RR of 0.51
(CI 0.40–0.66), the RR for all causes of mortality other than from breast
and ovarian cancers in the period 1958–1970 was 0.97 (CI 0.94–0.99)
(Table 2); 3) It is most unlikely that confounding could explain reduc-
tions in risk of themagnitudewe found—for example, the 70% reduction
in mortality in women under age 60.
4.2. Information Bias
Information bias also cannot explain the ﬁndings: 1) Region II is the
driest inhabited place on earth and everyone had to drink from themu-
nicipalwater sources. Exposuremisclassiﬁcation could not bias theﬁnd-
ings since virtually everyone in Region II was very highly exposed, and
there has never been any evidence of high concentrations of arsenic in
water in Region V; 2) Regarding misdiagnosis of cause of death on
death certiﬁcates, there would have to be a sudden reduction in classi-
fying breast cancer as a cause of death in Region II compared to Region
V starting in 1958, and a sudden reversal after 1970. There is no evi-
dence for this, and the mortality differences were most apparent in
younger women under the age of 60, when misdiagnosis of breast
cancer on death certiﬁcates is unlikely. In addition, Chile had (and still
has) uniformmedical training and health services throughout the coun-
try, including Region II and Region V.
4.3. Biological Plausibility
Li et al. and Chow et al. studied human breast cancerMCF-7 cells and
identiﬁed the inhibitory effects of arsenic trioxide on tumor cell prolifer-
ation (Li et al., 2004; Chow et al., 2004). They found no cytotoxic effects
on normal ﬁbroblast cells at these concentrations and they concluded
that arsenic trioxide might be a good candidate for treating breast can-
cer.Wang et al. reported that arsenic trioxide induces apoptosis inMCF7
cells in a time- and concentration-dependent manner (Wang et al.,
2011). In addition, ovarian cancer cell line studies have found them to
be responsive to arsenic trioxide (Liu et al., 2012). We assessed the
effects of arsenic trioxide on a variety of human cancer cell lines
representing major subtypes of breast cancer. In all cell lines tested,
As2O3 treatment suppressed tumor growth starting at concentrations
around 1 μM.Ourﬁndings are consistentwith those previously reported
by Xia et al. and Sun et al., both of which demonstrated the cytotoxic
effects of micromolar concentrations of arsenic trioxide in multiple
breast cancer cell lines (Xia et al., 2012; Sun et al., 2011). Here, we
also demonstrated cytotoxic effects on breast cancer cells resulting
from submicromolar concentrations of arsenic trioxide, in support of
the results of Ahn et al. (2010). We found that submicromolar levels
of arsenic trioxide signiﬁcantly impaired the triple negative breast can-
cer cell line MDA-MB-468 in a concentration-dependent manner.
The plausibility of our ﬁndings in Chile increased further when we
considered dose. In vitro assays often involve very high concentrations
of toxic agents, much higher than those experienced by humans in
daily life. However, the apoptotic effects of As2O3 on human breast can-
cer cells start in a few days at doses as low as 1–2 μM (2–4 μM of inor-
ganic arsenic), as seen in Fig. 2 and in previous studies (Xia et al.,
2012; Wang et al., 2011; Du et al., 2012; Li et al., 2004; Chow et al.,
2004). Women with breast cancer in Antofagasta in the years 1958–
1970 would have had continuous exposure with 1–2 μM of inorganic
arsenic in their urine (SupplementaryMaterials p 8), and probably com-
mensurate concentrations in organ tissues throughout their bodies. We
are not aware of any data on breast tissue arsenic concentrations, but
studies after acute poisoning ﬁnd arsenic to be distributed in most
organs throughout the body (Benramdane et al., 1999). It is also likely
that some methylated inorganic arsenic, in particular MMA and DMAin trivalent form, could contribute to breast cancer apoptosis in addition
to the activity of inorganic arsenic itself (Zhang et al., 2013).
Ovarian cancer shares with breast cancer several lifestyle and envi-
ronmental risk factors that are associated with endogenous and exoge-
nous hormone exposure (Zografos et al., 2004), and they also share
common genetic risk factors; family history is a risk factor for both.
Initially, we had not looked at ovarian cancer mortality in Chile because
it is relatively rare. However, when we did so, with a clear a priori
hypothesis that themortalitymight be reduced, we found that although
the numbers were small the trend was similar to that for breast cancer.
We know of no other human data on breast cancer mortality rates
associated with concurrent exposure to arsenic in drinking water. In
addition, as explained in Supplementary Materials p 9, any epidemio-
logical ﬁndings concerning arsenic and breast cancer mortality in
other populations are unlikely to add signiﬁcantly to the information
we present from Chile.
We suggest that the evidence from Chile, and from in vitro breast
cancer cell studies, is sufﬁcient to consider proceeding with a clinical
trial of patients with advanced breast cancer. We already have many
studies on long-term arsenic health effects, and the side effects associat-
ed with treatment of promyelocytic leukemia with arsenic are well-
known. Our ﬁndings from Chile suggest that high doses sometimes
used in treatment of promyelocytic leukemia would not be needed.
Intravenous doses of 10 mg of arsenic trioxide per day for leukemia pa-
tients result in urine total arsenic concentrations of 4,000 to 5,000 μg/g
creatinine in urine (Wang et al., 2013), whereas drinking water arsenic
concentrations of about 600 μg/L in our study in Chile resulted in urine
total arsenic concentrations of about 600 μg/g of creatinine (Biggs et al.,
1997). Importantly, this comparison suggests that inorganic arsenic in
drinking water in the treatment of breast cancer could be at much
lower doses than those given with intravenous therapy of promyelocytic
leukemia.5. Conclusions
We report a major reduction in breast cancer soon after high ex-
posure to inorganic arsenic in drinking water commenced in north-
ern Chile, which could not have resulted from confounding. Once
an arsenic removal plant was installed in themajor city of Antofagas-
ta, breast cancer mortality started to increase back to rates close to
that of the unexposed comparison population. Findings of in vitro
studies on human breast cancer give scientiﬁc plausibility to these
ﬁndings. We suggest that there is sufﬁcient supportive evidence to
embark on clinical trials of inorganic arsenic in the treatment of
advanced human breast cancer.Author Contributions
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